Drug intelligence / Profile preview

haploidentical stem cells + natural killer cells

Development stage
Unknown
Lead developer
Christian Medical College, Vellore
Modality
CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration
Intravenous
01

Overview

Haploidentical stem cells + natural killer (NK) cells refers to a combination cellular therapy in which hematopoietic stem cells from a haploidentical (half-matched, usually familial) donor are transplanted into a patient, often for the treatment of hematologic malignancies such as acute myeloid leukemia (AML), and are combined with an infusion of donor-derived NK cells. The rationale is that alloreactive NK cells can mediate antileukemic effects, enhance engraftment, and reduce relapse risk and graft-versus-host disease (GVHD). In this approach, patients typically receive cytoreductive or conditioning chemotherapy followed by sequential infusions of ex-vivo expanded or activated haploidentical NK cells prior to or after the stem cell transplant. This strategy is under investigation primarily for refractory AML and other high-risk blood cancers[1][2][3].

Other names
haploidentical hematopoietic stem cell transplantation plus natural killer cell therapyhaplo-HSCT + NK cell therapyhaploidentical NK cell adjunct to transplant
02

Targets

KIR2DS4 (Killer cell immunoglobulin-like receptor 2DS4)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))KLRC1 (Killer cell lectin-like receptor subfamily C member 1)NKG2D (Natural killer group 2 member D receptor)

Beyond the preview

Go deeper on haploidentical stem cells + natural killer cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haploidentical stem cells + natural killer cells.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call